GIG HARBOR, Wash., May 18, 2026 (GLOBE NEWSWIRE) — IP Strategy Holdings, Inc. (Nasdaq: IPST) (the “Company” or “IP Strategy”), the first company to adopt a treasury reserve policy centered on the $IP token, today announced that Chief Executive Officer Justin Stiefel and Chief Investment Officer Phil Blows will participate in a virtual fireside chat hosted by Jeff Cantwell of Seaport Research Partners on Thursday, May 21, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. Interested parties may register for the event here. About IP StrategyIP Strategy Holdings, Inc. (Nasdaq: IPST) is the first Nasdaq-listed company to hold $IP tokens as a primary reserve asset and operate a validator for the Story Protocol. The Company provides public market investors broad exposure to the $80 trillion programmable intellectual property economy in a regulated...

Israel Innovation Authority Approves Project Following Successful Real-World Construction Pilot Under EZRA International Group’s Scale51 Initiative LAKEWOOD, NJ, May 18, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced that Enquantum Ltd. (“Enquantum”), a developer of advanced networking and post-quantum cybersecurity technologies and a strategic platform investment under EZRA International Group’s Scale51 initiative, successfully completed a real-world private 5G deployment with a leading Israeli construction company. The deployment demonstrated advanced worker safety, real-time operational monitoring, and intelligent site management capabilities in active construction environments. As part of the pilot program, construction workers utilized 5G-connected...

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be at high risk for mpox infection. “We are pleased to receive this approval for ACAM2000® from SFDA for immunization against smallpox and mpox in high-risk individuals,” said Simon Lowry, chief medical...

THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. The accepted abstracts titled, “Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, further recognize the growing clinical and scientific interest in Autonomix’s differentiated approach to peripheral nerve modulation...

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension study. Based on a positive interim assessment demonstrating a Halneuron® 4-week treatment effect versus placebo, Dogwood previously submitted plans to FDA to support commencement of a Halneuron®...